Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Carlos L Arteaga

Showing results (1-10 of 342) with videos related to

Pageof 35
Sort By:
Current Topics in Microbiology and Immunology|July 2, 2010
Clinical development of phosphatidylinositol-3 kinase pathway inhibitorsCarlos L Arteaga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2006
Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?Carlos L Arteaga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Cdk inhibitor p27Kip1 and hormone dependence in breast cancerCarlos L Arteaga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2011
Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?Carlos L Arteaga
Current Opinion in Genetics & Development|December 27, 2005
Inhibition of TGFbeta signaling in cancer therapyCarlos L Arteaga
Seminars in Oncology|November 8, 2002
Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaCarlos L Arteaga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Progress in breast cancer: overviewCarlos L Arteaga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugsCarlos L Arteaga
Nature Medicine|June 1, 2004
Selecting the right patient for tumor therapyCarlos L Arteaga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?Carlos L Arteaga
Pageof 35

Showing results (1-10 of 342) with videos related to

Sort By:
Pageof 35
Current Topics in Microbiology and Immunology|July 2, 2010
Clinical development of phosphatidylinositol-3 kinase pathway inhibitorsCarlos L Arteaga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 19, 2006
Can trastuzumab be effective against tumors with low HER2/Neu (ErbB2) receptors?Carlos L Arteaga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|January 22, 2004
Cdk inhibitor p27Kip1 and hormone dependence in breast cancerCarlos L Arteaga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|June 15, 2011
Why is this effective HSP90 inhibitor not being developed in HER2+ breast cancer?Carlos L Arteaga
Current Opinion in Genetics & Development|December 27, 2005
Inhibition of TGFbeta signaling in cancer therapyCarlos L Arteaga
Seminars in Oncology|November 8, 2002
Overview of epidermal growth factor receptor biology and its role as a therapeutic target in human neoplasiaCarlos L Arteaga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|December 4, 2013
Progress in breast cancer: overviewCarlos L Arteaga
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 4, 2003
EGF receptor as a therapeutic target: patient selection and mechanisms of resistance to receptor-targeted drugsCarlos L Arteaga
Nature Medicine|June 1, 2004
Selecting the right patient for tumor therapyCarlos L Arteaga
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|February 24, 2007
Will single-time tumor profiling and a "guilt by association" approach allow us to outsmart HER2-positive breast cancer?Carlos L Arteaga
Pageof 35